Results 61 to 70 of about 139,634 (224)
Navigating challenges and opportunities in orphan medicines: A spotlight commentary on rare diseases
British Journal of Clinical Pharmacology, Volume 91, Issue 4, Page 1084-1087, April 2025.
Andrej Belančić +3 more
wiley +1 more source
South African Medical Journal, 2015 Gout is the most common crystal arthritis and its prevalence is rising. It is associated with the metabolic syndrome, and hyperuricaemia may be an independent risk factor for cardiovascular disease. The acute presentation of gout is easily managed, but the underlying cause is seldom addressed.Indications for initiating uric acid therapy have been ...
openaire +6 more sources
Comorbidity trajectories before and after the diagnosis of heart failure: A UK Biobank cohort study
European Journal of Heart Failure, EarlyView.Time of diagnosis of comorbidities in relation to heart failure. COPD, chronic obstructive pulmonary disease; MI, myocardial infarction. Abstract Aims Heart failure (HF) is frequently associated with multiple comorbidities. We aimed to define their trajectory of accrual to identify opportunities for disease prevention. Methods and results We identified
Hugo MacGowan +12 more
wiley +1 more source
Management of gout in a South Auckland general practice [PDF]
, 2014 BACKGROUND AND CONTEXT: In New Zealand, the highest prevalence of gout is in Maori and Pacific people. Counties Manukau District Health Board (CMDHB) has the highest Maori and Pacific population of any New Zealand District Health Board.
Arroll B, Reaves E
core
The International Journal of Health Planning and Management, EarlyView.ABSTRACT Purpose Post‐cancer treatment pain (PCTP) is prevalent among cancer survivors but remains understudied. It is critical to quantify PCTP prevalence over time and to estimate the resulting short and long‐term incremental healthcare expenditures (total, third‐party, and out‐of‐pocket) and out‐of‐pocket burden among cancer survivors.
Yves Paul Vincent Mbous +3 more
wiley +1 more source
Integrated safety studies of the urate reabsorption inhibitor lesinurad in treatment of gout. [PDF]
, 2019 ObjectiveLesinurad (LESU) is a selective urate reabsorption inhibitor approved at 200 mg daily for use with a xanthine oxidase inhibitor (XOI) to treat hyperuricaemia in gout patients failing to achieve target serum urate on XOI. The aim of the study was
Baumgartner, Scott +8 more
core +1 more source
The International Journal of Health Planning and Management, EarlyView.ABSTRACT Background The prevalence of high body mass index (BMI) contributes to an increased risk of various diseases. This study aimed to identify global disease burden trends associated with high BMI from 1990 to 2019 and forecasts up to 2040. Methods Using data from the global burden of disease (GBD) 2019 study, we analysed the number and ratio of ...
Eun‐Ji Kim +4 more
wiley +1 more source
Risk Factors in the Incidence of Gouty Arthritis in Masohi Town, Central Maluku Regency in 2010 [PDF]
, 2012 The gouty arthritis incidence rate in Masohi Townof Central Maluku Regency is 54 people based on the data from the general hospital in Masohi. The aim of study was to find out the risk factor in the incidence of gouty arthritis in Masohi Town of ...
Amiruddin, R. (Ridwan) +2 more
core +1 more source
Gout in pregnancy: Obstetric and neonatal outcomes
International Journal of Gynecology &Obstetrics, Volume 169, Issue 1, Page 349-355, April 2025.Abstract Objective The pregnancy, delivery, and neonatal outcomes of pregnancies complicated by gout have yet to be evaluated in a population‐based study. We sought to evaluate the obstetric and neonatal outcomes in pregnant patients with gout using a national population database.
Sam Amar +3 more
wiley +1 more source